Invitae Corporation (NVTA)
After hours:
| Previous Close | 0.5929 |
| Open | 0.5900 |
| Bid | 0.5800 x 1400 |
| Ask | 0.5900 x 1000 |
| Day's Range | 0.5760 - 0.6099 |
| 52 Week Range | 0.3600 - 2.9400 |
| Volume | |
| Avg. Volume | 9,783,669 |
| Market Cap | 167.942M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.3600 |
| Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.31 |
Motley FoolBetter Growth Stock: CRISPR Therapeutics vs. Invitae
Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. You'll find a lot of these candidates in the area of biotech, and two possibilities that come to mind right now are gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) and genetic-testing specialist Invitae (NYSE: NVTA). Which is the better growth stock to buy now?
Insider MonkeyInvitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript
Invitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript November 8, 2023 Invitae Corporation beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.3. Operator: Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today’s call. We will have a […]
